Tesamorelin (Egrifta)
Overview
A synthetic GHRH analog consisting of the 44-amino acid sequence of human GHRH with a trans-3-hexenoic acid modification at the N-terminus to improve stability. Tesamorelin specifically targets visceral adipose tissue reduction by stimulating lipolysis through GH-mediated pathways.
Mechanism of Action
It is the only FDA-approved treatment for HIV-associated lipodystrophy.
Research Summary & Key Findings
FDA-approved in 2010 for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Clinical trials showed 15-18% reduction in visceral adipose tissue. Also demonstrated improvements in liver fat content in patients with NAFLD in Phase 2 studies.
Clinical Status
Tesamorelin (Egrifta) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.
Administration Routes
References
Primary literature
- PubMed — "Tesamorelin"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov — "Tesamorelin"
Registered interventional and observational studies, including status and phase.
- PubChem — "Tesamorelin"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Hormone
CJC-1295
In Clinical TrialsA synthetic analog of growth hormone-releasing hormone (GHRH) with a Drug Affinity Complex (DAC) that binds to albumin, ...
View detailsIpamorelin
In Clinical TrialsA highly selective growth hormone secretagogue that acts on ghrelin/GHS receptors in the pituitary gland to stimulate GH...
View detailsSermorelin
FDA ApprovedA synthetic 29-amino acid analog of GHRH representing the shortest fully functional fragment of the native 44-amino acid...
View detailsPT-141 (Bremelanotide / Vyleesi)
FDA ApprovedA synthetic cyclic heptapeptide melanocortin receptor agonist that activates MC3R and MC4R in the central nervous system...
View detailsStart Your Consultation
Get an AI-proposed Tesamorelin (Egrifta) protocol reviewed by a physician in our network.
Start Your ConsultationFind a Pharmacy
Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Tesamorelin (Egrifta).
Pharmacy DirectoryJoin the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.